ZFP90 drives the initiation of colitis-associated colorectal cancer via a microbiota-dependent strategy

• Main Authors: Ji-Xuan Han, Zhi-Hang Tao, Yun Qian, Chen-Yang Yu, Jialu Li, Zi-Ran Kang, Shiyuan Lu, Yuanhong Xie, Jie Hong, Haoyan Chen, Ying-Xuan Chen, Jing-Yuan Fang
• Format: Article
• Language: English
• Published: Taylor & Francis Group 2021-01-01
• Series: Gut Microbes
• Subjects: zfp90; gut microbiota; colitis-associated colorectal cancer; gut barrier; prevotella copri
• Online Access: http://dx.doi.org/10.1080/19490976.2021.1917269
• ISSN: 1949-0976; 1949-0984

Chronic inflammation and gut microbiota dysbiosis are risk factors for colorectal cancer. In clinical practice, patients with inflammatory bowel disease (IBD) have a greatly increased risk of developing colitis-associated colorectal cancer (CAC). However, the underlying mechanism of the initiation of CAC remains unknown. Systematic analyses using an existing genome-wide association study (GWAS) and conditional deletion of Zfp90 (encoding zinc finger protein 90 homolog) in a CAC mouse model indicated that Zfp90 is a putative oncogene in CAC development. Strikingly, depletion of the gut microbiota eliminated the tumorigenic effect of Zfp90 in the CAC mouse model. Moreover, fecal microbiota transplantation demonstrated that Zfp90 promoted CAC dependent on the gut microbiota. Analysis of 16s rDNA sequences in fecal specimens from the CAC mouse model allowed us to speculate that a Prevotella copri-defined microbiota might mediate the oncogenic role of Zfp90 in the development of CAC. Mechanistic studies revealed Zfp90 accelerated CAC development through the TLR4-PI3K-AKT-NF-κB pathway. Our findings revealed the crucial role of the Zfp90-microbiota-NF-κB axis in creating a tumor-promoting environment and suggested therapeutic targets for CAC prevention and treatment.